Aetna modified CPB 0962 covering afamelanotide (Scenesse) under HCPCS code J7352, effective December 10, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated its Scenesse coverage policy under CPB 0962 Aetna system. The revision tightens the medical necessity criteria around biochemical confirmation requirements for erythropoietic protoporphyria (EPP). If your practice bills J7352 for afamelanotide implants, this policy change directly affects your prior authorization documentation and your risk of claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Afamelanotide (Scenesse) — CPB 0962 |
| Policy Code | CPB 0962 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | High — narrow covered population, specific lab threshold required |
| Specialties Affected | Hematology, Dermatology, Rare Disease/Metabolic Disorders |
| Key Action | Confirm protoporphyrin lab values are documented above reference range before submitting J7352 claims |
Aetna Afamelanotide Coverage Criteria and Medical Necessity Requirements 2025
The Aetna afamelanotide coverage policy covers exactly one indication: biochemically confirmed erythropoietic protoporphyria in adults. That's it. And "biochemically confirmed" isn't just a checkbox — Aetna requires that the member's protoporphyrin level sits above the lab reference range in peripheral red blood cells.
This is a narrow, specific threshold. If the lab report doesn't show an above-range protoporphyrin level, Aetna will not consider J7352 medically necessary. You need that lab value documented in the record before you submit.
The medical necessity bar here has two hard requirements: the patient must be an adult, and the lab result must show protoporphyrin above the reference range. Meeting one without the other gets you a denial. Prior authorization is the expected pathway for a drug this specialized — make sure your prior auth package leads with the biochemical confirmation, not just the diagnosis code.
Afamelanotide billing under this policy is essentially an all-or-nothing proposition. Aetna's reimbursement pathway is limited to this single indication, and there is no gray area in the criteria. This is actually cleaner than some rare-disease drug policies, where criteria are vague and leave room for interpretation. The specificity here helps — you know exactly what documentation you need.
Aetna Afamelanotide Exclusions and Non-Covered Indications
Aetna's position is blunt: all other indications for afamelanotide are experimental, investigational, or unproven. There's no partial coverage, no case-by-case exception pathway for off-label use mentioned in CPB 0962.
This matters for billing teams because Scenesse has been studied in other porphyria subtypes and some photodermatology contexts. Don't assume a patient with a related diagnosis gets coverage. If the diagnosis isn't biochemically confirmed EPP with above-range protoporphyrin in peripheral red blood cells, the claim will be denied.
The experimental designation covers everything outside that one indication. Document your denial workflow now for any off-label requests you receive after the December 10, 2025 effective date.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Biochemically confirmed EPP, adult, protoporphyrin above lab reference range in peripheral red blood cells | Covered | J7352, E80.0 | Prior auth required; lab documentation of above-range protoporphyrin is mandatory |
| EPP in members under 18 | Not Covered | — | Adult members only per CPB 0962 |
| All other indications for afamelanotide | Experimental / Not Covered | — | Aetna considers all non-EPP uses unproven |
| Continuation of therapy with demonstrated benefit | Covered | J7352, E80.0 | Member must show ongoing benefit from afamelanotide; document at each continuation request |
Aetna Afamelanotide Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your J7352 claim history before December 10, 2025. Pull all active and pending afamelanotide claims. Confirm each has documented biochemical confirmation — specifically, a lab result showing protoporphyrin above the reference range in peripheral red blood cells. Any claim without that lab value is a denial waiting to happen. |
| 2 | Update your prior authorization checklist for J7352. Your PA request needs three things: adult patient confirmed, ICD-10 E80.0 as the diagnosis, and the protoporphyrin lab result showing above-reference-range values. Make this a hard stop in your workflow — no PA submission leaves without all three. |
| 3 | Train your billing team on the "above reference range" requirement. This is the single most likely failure point. A positive EPP diagnosis alone doesn't satisfy Aetna's criteria. The lab value must be above the reference range. If your clinical team pulls a lab showing elevated-but-in-range values, that's a documentation gap you need to address before submission. |
| 4 | Build a continuation-of-therapy documentation process now. Aetna covers continuation for members who are experiencing benefit. That phrase — "experiencing benefit" — needs to be in the clinical notes at every renewal cycle. Work with your prescribing physician to define what "benefit" looks like for each patient and capture it explicitly in the record. |
| 5 | Flag any off-label Scenesse requests immediately. If a prescriber submits for an indication outside biochemically confirmed EPP, route it to your compliance officer before billing. Aetna's experimental designation is absolute here. Submitting J7352 for an off-label use under this policy creates claim denial risk and potentially more serious compliance exposure. |
| 6 | Review the related policies — CPB 0596 (Liver Transplantation) and CPB 0871 (Hematopoietic Cell Transplantation for Inherited Metabolic Disorders). EPP can progress to liver disease. If your patient population includes severe EPP cases, you may eventually encounter these policies alongside CPB 0962. Understand how they interact before you're managing a complex claim mid-cycle. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Afamelanotide Under CPB 0962
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J7352 | HCPCS | Afamelanotide implant, 1 mg |
J7352 is the only billing code covered under this policy. Bill it only when the patient meets all criteria: adult age, biochemically confirmed EPP, and protoporphyrin above the lab reference range in peripheral red blood cells.
Key ICD-10-CM Diagnosis Codes
The policy data includes three ICD-10-CM codes. Two of them require direct attention from your billing team. The third is a red flag.
| Code | Description | Notes |
|---|---|---|
| E80.0 | Hereditary erythropoietic porphyria | Primary covered diagnosis for J7352 under CPB 0962 |
| A49.02 | Methicillin resistant Staphylococcus aureus infection, unspecified site | Listed in policy data — does NOT support J7352 coverage; review any claim pairing this code with afamelanotide |
| I63.9 | Cerebral infarction, unspecified | Listed in policy data — does NOT support J7352 coverage; no clinical rationale for pairing with afamelanotide |
The presence of A49.02 and I63.9 in this policy's code table deserves a second look. These codes — MRSA infection and cerebral infarction — have no obvious clinical connection to erythropoietic protoporphyria or afamelanotide. Their inclusion may reflect back-end policy system architecture rather than clinical intent.
Don't pair J7352 with A49.02 or I63.9 expecting coverage. E80.0 is your covered diagnosis. If you're unsure how these codes apply to your specific claims mix, loop in your compliance officer before the effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.